Expert Financial Analysis and Reporting

Recent Reports

• AMAG Pharmaceuticals: Trying to Project 2019 Sales for the Makena Franchise (AMAG, $24.45, Buy) (0)

Recent Blogs

• Update on Currently Recommended Stocks of SmithOnStocks.com (0)
• Cryoport: Reiterating My Buy Recommendation (CYRX, Buy, $14.20) (0)
• Novartis Releases Three Month Interim Data for JULIET Trial of CTL-019 in r/r DLBCL (0)
• Cytokinetics: Update based on 2Q, 2018 Conference Call (CYTK, Buy, $6.85) (0)
• FDA Announces July 12 AdCom Meeting for CTL-019: Thoughts on How This Might Affect Investor Perceptions of Kite (KITE, Neutral, $80.25) and Cryoport (CYRX, Buy, $3.89) (0)
• Portola: Update and Reiteration of Buy Recommendation (PTLA, Buy, $39.31) (0)
• Northwest Biotheraputics to Make Presentation at ASCO Today Monday June 5, 2017 (0)
• AMAG Pharmaceuticals: Strong Launch of Subcu Makena and Pending Sale of Cord Blood Registry is Encouraging (AMAG, $23.55, Buy) (0)
• Key Investment Considerations Relating to Much Anticipated CAR-T Product Launches By Kite and Novartis Later This Year (0)
• Northwest Biotherapeutics: There could be Overwhelming Patient Demand for DCVax-L due to the Right to Try law (NWBO, $0.24, Buy) (0)
• Cytokinetics: Comments on the Upside Move Today (CYTK, Buy, $12.90) (0)

Social Feeds

• • $NWBO Patient demand for DCVax-L under Right to Try law could be overwhelming. Each 100 patients treated could g… https://t.co/w04ue7hSfd, Jun 13
  • $NWBO Five Spectacular Patient Outcomes for Patients Treated with DCVax-L as Reported at ASCO See the report at… https://t.co/MfIpnAJM8W, Jun 05
  • $nwbo After listening to the testimonials on the webcast, I think that this will go viral and many, many GBM patien… https://t.co/HoR7ymIzvf, Jun 04
  • $NWBO Right to Try Law Potentially Could Lead to Meaningful Revenues Prior to Formal Approval of DCVax-L https://t.co/F1Az4pfVGx, Jun 03
  • $NWBO Temp website hack resolved. See new rprt Blinded Data from Phase 3 Trial Strongly Suggests that DCVax-L is a… https://t.co/upRUAlnwLY, May 30